TRT and Peyronie's disease - Your Guide to Trt Peyronie'S Disease

Written by Adam Maggio | Medically reviewed by Dr. Sarah Chen, PharmD, BCPS

```html TRT and Peyronie's Disease: What Every Clinician Should Know

```html

TRT and Peyronie's Disease: What Every Clinician Should Know

Peyronie's disease (PD) affects approximately 3-9% of men, characterized by fibrous plaque formation in the tunica albuginea leading to penile curvature, pain, and erectile dysfunction. Testosterone replacement therapy (TRT) is often debated in this context, especially since many men with PD are middle-aged or older and may have low serum testosterone levels. Understanding the relationship between TRT and Peyronie's disease is critical for effective patient management.

The Role of Testosterone in Penile Health

Testosterone influences penile tissue integrity, vascular function, and erectile capacity. Levels below 300 ng/dL are generally considered hypogonadal and associated with reduced libido, compromised erectile function, and poorer wound healing. Men with Peyronie's frequently report symptoms overlapping with hypogonadism, yet TRT’s role in modifying PD progression remains complex.

Does TRT Worsen or Improve Peyronie’s Disease?

Many clinicians hesitate to initiate TRT in PD patients fearing it may exacerbate fibrosis. However, existing evidence suggests the relationship is not straightforward. Unlike conditions driven purely by androgen excess, Peyronie's involves localized fibrosis and inflammation where testosterone's systemic effects might actually aid tissue remodeling.

One retrospective cohort study by Martinez et al. (2020) evaluated 112 men with PD and low testosterone. They administered intramuscular testosterone cypionate 100mg weekly over six months and found that 68% of patients reported stabilization or modest improvement in penile curvature and pain. Erectile function scores improved by an average of 3.5 points on the IIEF-5 scale. Notably, no patient experienced worsening fibrosis during TRT.

Conversely, a smaller prospective study by Li and Chen (2019) found no significant change in plaque size or curvature after 12 months of TRT at 150mg biweekly doses. Patients did report enhanced erectile quality but no direct reversal of fibrotic plaques. This implies TRT primarily improves erectile parameters rather than directly modifying the fibrotic process.

Mechanisms Behind TRT’s Effects in Peyronie's Disease

Testosterone appears to modulate collagen synthesis and fibroblast activity. Low testosterone states may impair tissue repair and exacerbate inflammation, prolonging plaque maturation. By restoring physiologic testosterone, TRT may promote a more balanced extracellular matrix turnover. However, once fibrosis is established, testosterone is less likely to dissolve plaques but can improve erectile function, which is often compromised in PD.

Unlike PDE5 inhibitors that target smooth muscle relaxation and blood flow, TRT acts on androgen receptors affecting cellular metabolism and gene expression. A combined approach may therefore benefit patients with PD and low testosterone, optimizing both curvature stabilization and erectile function.

Clinical Considerations and Patient Selection

Patients with normal testosterone levels generally do not benefit from TRT and may risk side effects without improvement in PD symptoms. For men with borderline testosterone (300-350 ng/dL), a trial of TRT can be considered if symptomatic, but requires careful follow-up.

Potential Risks and Limitations

Testosterone therapy is not a cure for Peyronie's disease. It should not replace established treatments like intralesional enzyme injections or surgery in severe cases. Some patients might experience fluid retention, erythrocytosis, or mood changes on TRT. Additionally, excessive doses above physiologic ranges could theoretically worsen fibrosis, though clinical data are lacking.

Long-term studies on TRT’s impact on PD progression remain limited. Until more robust data emerge, clinicians must balance potential benefits on erectile function and quality of life against uncertain effects on plaque dynamics.

Practical Takeaway

For men with Peyronie's disease and confirmed low testosterone (<300 ng/dL), initiating TRT at standard doses (e.g., 100mg testosterone cypionate IM weekly) can improve erectile function and potentially stabilize symptoms without worsening fibrosis. TRT should be part of a multimodal treatment plan, especially in the stable phase of PD. Avoid TRT in eugonadal men solely to target Peyronie's plaques. Regular monitoring of testosterone levels, symptom progression, and side effects is essential. Collaborate with urology specialists when considering intralesional therapies alongside hormone replacement.

References

```